Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protein Based Pneumococcal Vaccine
- Development stage
- Phase 1
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Protein Based Pneumococcal Vaccine (PBPV) is a vaccine developed by CanSino Biologics Inc. to prevent infections caused by *Streptococcus pneumoniae*. These infections can lead to serious health problems, particularly in infants and the elderly. The vaccine aims to address the limitations of traditional polysaccharide-based vaccines, which often fail to cover all polysaccharide types, especially in adults, by utilizing a protein-based approach to induce an immune response.
- Other names
- recombinant pneumococcal protein vaccine
02
Targets
Ply (Pneumolysin)PspA (Pneumococcal surface protein A)S. pneumoniae (Streptococcus pneumoniae)
Beyond the preview
Go deeper on Protein Based Pneumococcal Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein Based Pneumococcal Vaccine.